Skip to main content

Drug Interactions between mefloquine and posaconazole

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

mefloquine posaconazole

Applies to: mefloquine and posaconazole

Consumer information for this interaction is not currently available.

CONTRAINDICATED: Coadministration with posaconazole may increase the plasma concentrations of CYP450 3A4 substrates that can prolong the QT interval, possibly resulting in QT prolongation and cases of torsade de pointes (TdP). The underlying mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by posaconazole. In general, the risk of an individual agent or a combination of agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia). In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).

MANAGEMENT: Coadministration of posaconazole with CYP450 3A4 substrates that can prolong the QT interval is considered contraindicated.

References

  1. "Product Information. Noxafil (posaconazole)." Schering-Plough Corporation (2006):
  2. Agencia Española de Medicamentos y Productos Sanitarios Healthcare "Centro de información online de medicamentos de la AEMPS - CIMA. https://cima.aemps.es/cima/publico/home.html" (2008):
  3. "Product Information. Posaconazole (AKM) (posaconazole)." Pharmacor Pty Ltd (2022):
  4. "Product Information. Posaconazole (posaconazole)." Morningside Healthcare Ltd (2024):
  5. "Product Information. Posaconazole (posaconazole)." Eugia US LLC (2023):
  6. "Product Information. Gln-Posaconazole (posaconazole)." Glenmark Pharmaceuticals Canada Inc (2023):
View all 6 references

Drug and food interactions

Moderate

mefloquine food

Applies to: mefloquine

Food can enhance the levels of mefloquine in your body. Take mefloquine immediately after a meal. This will make it easier for your body to absorb the medication. Take each dose with a full glass, at least 8 ounces (240 mL) of water. For children or those who have difficulty swallowing, mefloquine can be crushed and mixed with water or sugar water. Talk to your healthcare provider if swallowing the tablets is difficult.

Switch to professional interaction data

Moderate

posaconazole food

Applies to: posaconazole

Food significantly increases the absorption of posaconazole from the tablet or suspension formulations. The manufacturer recommends that you take the tablet with food and the oral suspension during or immediately (within 20 minutes) after a full meal. If you cannot eat a full meal, you should take the oral suspension with a liquid nutritional supplement like Ensure or an acidic carbonated beverage like ginger ale. Do not take these medications on an empty stomach, as it may lead to inadequate blood levels and reduced effectiveness. Ask your doctor before using alcohol together with posaconazole from delayed release suspension formulations as this may cause an increase in side effects. Talk to your doctor or pharmacist if you have any questions on how to use the medication properly.

Switch to professional interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer